Home
  • Our Company
    • Biopharmaceutical Acceleration Model®
    • Dynamic Assembly®
    • Kinetic™
    • Syneos One®
    • The Trusted Process®
    • Our Leadership
    • Our Vision, Mission and Values
    • Resource Library
    • Events
    • Awards
    • Site Relationships
    • Our Office Locations
  • Solutions
    • Clinical Development
      • Full Service
        • Decentralized Solutions
        • Bioanalytical Solutions
        • Early Phase
        • Phase II - III
        • Phase IIIb - IV
        • Real World and Late Phase
        • Medical Device and Diagnostics
      • FSP 360
        • Biostatistics and Statistical Programming
        • Clinical Data Management
        • Clinical Development Services Project Management
        • Clinical Monitoring
        • Drug Safety and Pharmacovigilance
        • Investigator Management Solutions
        • Medical Writing and Communications
        • Rater Training
        • Site Start Up
        • Site and Patient Access
        • Trial Master File Operations
    • Commercialization
      • Advertising
      • AnswerSuite
      • Behavioral Insights
      • Brand Commercialization
      • Brand Naming and Development
      • Clinical Field Teams
      • Commercial Model of the Future
      • Commercial Recruiting Solutions
      • Communications
      • Deployment Solutions
      • Digital and Social Media
      • Full-Service Commercial
      • Health Economics and Outcomes Research
      • Medical Affairs Transformation
      • Medical Communications
      • Policy and Advocacy
      • Portfolio Strategy
      • Public Relations
      • REMS and Risk Management (PMO)
      • Reputation and Risk Management
      • Selling Solutions
      • Training and Learning Solutions
      • Value and Access
    • Consulting
      • Commercial Advisory Group
        • Portfolio Strategy and Transactions
        • Health Economics and Outcomes Research
        • Product and Franchise Strategy
        • Value and Access
        • Customer and Digital Engagement
      • Scientific and Medical Affairs Advisory Group
        • Medical Affairs
        • Quality and Compliance
        • Regulatory
      • Risk and Program Management Advisory Group
        • REMS and Risk Management (PMO)
      • R&D Advisory Group
        • Research and Development
    • Syneos One®
  • Therapeutic Expertise
    • Therapeutic Areas
      • Cardiovascular
      • Central Nervous System
        • CNS Analgesia
        • CNS Clinical Surveillance Team
        • CNS Neurology
        • CNS Psychiatry
      • Endocrine and Metabolic
      • Gastroenterology
      • Immunology and Inflammation
      • Infectious Disease and Vaccines
      • Ophthalmology
      • Respiratory
      • Women's Health
      • Oncology and Hematology
        • Targeted Therapies
        • Novel and Emerging Therapies
        • Immuno-Oncology
    • Cross-Functional Solutions
      • Biosimilars
      • Cell and Gene Therapy
      • Patient Voice
      • Pediatrics
      • Rare Diseases
    • Our Experience Hub
  • Insights Hub
  • Careers
  • インサイト ハブ
  • 中途採用
  • 新卒採用 (日本)
  • News
    • In The News
    • Press Releases
    • Press Kit
  • Investors
  • Investigators
  • Transparency
  • Suppliers
    • Supplier Code of Conduct
    • Standard Contractual Clauses for Suppliers
    • Supplier Diversity and Inclusion
    • Supplier Terms and Conditions
  • Contact
  • English
  • Français Canadien
  • 日本語

Search form

Home Insights Hub The 2021 Health Trends Series The Race to Return Safe
Trends

The Race to Return Safe

December 17, 2020
Content 

 

Subscribe to our Newsletter

The Race to Return Safe

2021 Health Trends

Columns 
Content 
Image or Video 

Trends_2021_08.png

Race to Return Safe
Content 

Our industry’s response to COVID-19 has changed the global conversation about the impact pharmaceutical development has on lives and families. Today, we’re seeing a resurgence in public faith in medical innovation as companies race to develop diagnostics, treatments and vaccines in what we all hope will be record time.

 

2021 represents a critical pivot point where life sciences either builds on this new awareness of discovery and clinical participation or fights through a battle of vaccine hesitancy. This year, we do the work to show the impact, safety, integrity and mission the industry has long been committed to. The longer-term impact is stronger relationships with the advocates, prescribers and patients we all serve.

Critical Question

How do we leverage this moment of industry impact to build enduring trust and a strong understanding of the need to participate in clinical development?

Sparks for The Race to Return Safe

Columns 
Content 
Image or Video 

08_RaceToReturnSafe_01.png

The Race to Return Safe - 73%

73%: In April, just as COVID-19 was dramatically changing behaviors and outlooks around the world, the annual Trust Barometer report fielded a spring update and found a record-breaking level of trust for the pharmaceutical industry, with the biggest increases in trust in Canada, Germany and the U.S.

- PM Live, 2020

Content 
Image or Video 

08_RaceToReturnSafe_02.png

The Race to Return Safe - one in three

1:3 - As progress toward a cure advances, the debate about who will take it grows louder. In early fall polling, 35% of Americans said that they would not take a COVID-19 vaccine, even if the FDA approved and provided it at no cost. 1:6 people in the UK agreed, saying they are unlikely to or definitely will not get the vaccine.

— Gallup, 2020; Euronews, 2020

 

Download a PDF of this content below. 

 

The 2021 Health Trends Series
Remote Care
Pivot Past the Pandemic
Download
Previous Next

Fill out the form below to download your requested Insights Hub Article.

*Required fields

By submitting this form, you agree to our Terms & Conditions and Privacy Policy of our website. You can withdraw your consent at any time. If you have any questions, please Contact Us.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chapters

Chapter:
1
Remote Care
Chapter:
2
The Race to Return Safe
Chapter:
3
Realigning in Real Time
Chapter:
4
Post-Surge Capacity
Chapter:
5
The Next Normal
Chapter:
6
Fast Launch; Long Tail

Pages

  • 1
  • 2
  • 3
  • 4
  • next ›
  • last »
Branded Logo
Contact Us Today Share

Related Content

The 2021 Health Trends Series
July 1, 2021
Remote Care
December 1, 2020
Pivot Past the Pandemic
April 21, 2020
Interested in Syneos Health?
Get In Touch
Connect
  • LinkedInLinkedIn
  • TwitterTwitter
  • FacebookFacebook
  • InstagramInstagram

Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs and commercial capabilities to address modern market realities. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. We support a diverse, equitable and inclusive culture. Contact Us

Our Headquarters
Corporate Headquarters
  • 1030 Sync Street
  • Morrisville, NC 27560
  •  
  • Phone: +1 919 876 9300
  • Fax: +1 919 876 9360
  • Toll-Free: +1 866 462 7373
Menu
  • Solutions
  • Therapeutic Expertise
  • Brand Directory
  • 労働者派遣法に基づく情報公開
  • Careers
  • Study Participants
  • Media
  • Business Ethics Helpline
  • Events
  • Transparency
© 2022 Syneos Health. All Rights Reserved.
  • Terms Of Use
  • Privacy Notice
  • Privacy Shield
  • Online Tracking Opt-Out